Callan Capital LLC Has $1.66 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Callan Capital LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,100 shares of the medical instruments supplier’s stock after buying an additional 61 shares during the period. Callan Capital LLC’s holdings in Becton, Dickinson and Company were worth $1,659,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $29,000. Scarborough Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $32,000. Rise Advisors LLC bought a new stake in Becton, Dickinson and Company in the first quarter worth approximately $38,000. Finally, ICA Group Wealth Management LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $42,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX stock opened at $234.63 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The business has a 50-day simple moving average of $235.42 and a two-hundred day simple moving average of $235.54. The company has a market capitalization of $67.81 billion, a P/E ratio of 51.68, a price-to-earnings-growth ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.96 earnings per share. Research analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BDX. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup decreased their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Finally, Evercore ISI cut their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.